Atea Pharmaceuticals, Inc. - common stock (AVIR)
AVIR moved a median of +0.32% 30 minutes after news, and 0.00% by the close. How AVIR actually reacts to news — the realized, point-in-time move the market made, measured across 210 labeled events over the last three years with zero look-ahead.
AVIR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.51% | 61% | 210 |
| 30-min | +0.32% | 55% | 210 |
| 60-min | +0.41% | 56% | 210 |
| to close | 0.00% | 49% | 207 |
| Middle 50% of AVIR reactions | -0.61% to +1.18% |
|---|---|
| Median reaction (30-min) | +0.32% |
| Measured reactions | 210 |
Half of all Atea Pharmaceuticals, Inc. - common stock news events land between -0.61% and +1.18% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AVIR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AVIR's baseline. Nothing else.
Recent AVIR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | -2.41% | -2.07% | |
| Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.65% | -2.69% | |
| Form 10-Q Atea Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.65% | -2.69% | |
| Form 8-K Atea Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +3.65% | -2.69% | |
| Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 | Press release | GlobeNewswire | -0.21% | +0.85% | |
| Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus | Press release | GlobeNewswire | -2.27% | -6.63% | |
| Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus | Press release | GlobeNewswire | -1.90% | -1.05% | |
| Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus | Press release | GlobeNewswire | -2.00% | -3.12% | |
| Form 8-K Atea Pharmaceuticals, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | +2.52% | |
| Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 | Press release | GlobeNewswire | -1.76% | +0.00% | |
| Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline | Press release | GlobeNewswire | -4.38% | -12.95% | |
| Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.38% | -12.95% | |
| Form 10-Q Atea Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.38% | -12.95% | |
| Form 8-K Atea Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -4.38% | -12.95% | |
| Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 | Press release | GlobeNewswire | +0.26% | -2.27% | |
| Form DEF 14A Atea Pharmaceuticals, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.37% | +4.10% | |
| Form DEFA14A Atea Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.37% | +4.10% | |
| Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +6.64% | +22.20% | |
| Form 10-K Atea Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.64% | +22.20% | |
| Form 8-K Atea Pharmaceuticals, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +6.64% | +22.20% | |
| Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 | Press release | GlobeNewswire | -0.87% | +1.96% | |
| Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 | Press release | GlobeNewswire | +0.00% | +0.43% | |
| Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.45% | +4.94% | |
| Form 8-K Atea Pharmaceuticals, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | +4.94% | |
| Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.59% | +0.59% | |
| Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus | Press release | GlobeNewswire | +0.00% | +0.64% | |
| Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +0.00% | +3.96% | |
| Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.50% | — | |
| Form 10-Q Atea Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.50% | — | |
| Form 8-K Atea Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +2.50% | — | |
| Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 | Press release | GlobeNewswire | +1.25% | +1.87% | |
| Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 | Press release | GlobeNewswire | +0.70% | +1.25% | |
| Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 | Press release | GlobeNewswire | +0.00% | +0.31% | |
| Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 | Press release | GlobeNewswire | +0.00% | +2.06% | |
| Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.69% | +1.49% | |
| Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.56% | -6.11% | |
| Form 10-Q Atea Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.56% | -6.11% | |
| Form 8-K Atea Pharmaceuticals, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -6.11% | |
| Form S-8 Atea Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.56% | -6.11% | |
| Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 | Press release | GlobeNewswire | -0.96% | -0.55% | |
| Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America | Press release | GlobeNewswire | +0.90% | +1.20% | |
| Form 8-K Atea Pharmaceuticals, For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | +2.15% | |
| Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.86% | -9.31% | |
| Form 10-Q Atea Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.86% | -9.31% | |
| Form 8-K Atea Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | -9.31% | |
| Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 | Press release | GlobeNewswire | +0.36% | -3.21% | |
| Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 | Press release | GlobeNewswire | -1.35% | +0.67% | |
| Form DEF 14A Atea Pharmaceuticals, For: Jun 20 | SEC filing · Form DEF | SEC EDGAR | +0.34% | +1.38% | |
| Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 | Press release | GlobeNewswire | +1.20% | -2.40% | |
| Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program | Press release | GlobeNewswire | +0.65% | -4.19% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AVIR section they belong to.
Where else AVIR is measured.
AVIR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Atea Pharmaceuticals, Inc. - common stock's median reaction calculated?
Every labeled AVIR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 210 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of AVIR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AVIR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.